Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Redaporfin PDT in advanced head and neck cancer
NCT02070432Phase 2Unknown
- Sponsor
- Luzitin
- Start
- Feb 2014
- Primary completion
- Jul 2016
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of redaporfin in head and neck squamous cell carcinoma (HNSCC), sponsored by Luzitin. Primary endpoint: Number of Participants With Adverse Events. Status: unknown.
02
Drugs
redaporfin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02070432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070432.